SAB Biotherapeutics is a clinical-stage biopharmaceutical development company.
SAB Biotherapeutics has raised $85.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in March 2026.
SAB Biotherapeutics's investors include RA Capital Management, Vivo Capital, Sanofi, RTW Investments, Commodore Capital.
SAB Biotherapeutics is headquartered in Sioux Falls, United States.
SAB Biotherapeutics is a clinical-stage biopharmaceutical development company.
SAB Biotherapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"SAB Biotherapeutics — Funding & Investors." VCBacked, March 17, 2026, https://www.vcbacked.co/company/sab-biotherapeutics. Accessed September 30, 2026.
VCBacked. (2026). SAB Biotherapeutics — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/sab-biotherapeutics
{{cite web |title=SAB Biotherapeutics — Funding & Investors |url=https://www.vcbacked.co/company/sab-biotherapeutics |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated